BioMedNewsBreaks — Earth Science Tech, Inc. (OTC: ETST) Shareholders Approve Uplisting Strategy, Series B Preferred Stock Retirement

Earth Science Tech (OTC: ETST) announced voting results from its first Annual Meeting of Stockholders, held virtually Aug. 31, 2026. Shareholders approved the company pursuit of a reverse stock split, valid for 12 months and to be used only if the board determines it is necessary to meet minimum bid-price requirements for an uplisting to a national securities exchange. Shareholders also authorized the board independent Special Committee to negotiate the retirement of the Series B Preferred Stock, which the company said would eliminate its dual-class, super-voting control structure.

Shareholders also approved the company cash-only “Say-on-Pay” executive compensation structure and elected a three-year review cycle, re-elected all seven director nominees and ratified Semple, Marchal & Cooper, LLP as the independent registered public accounting firm. Earth Science Tech said an audio replay of the meeting includes management guidance, additional detail on the approved proposals and a shareholder question-and-answer session.

To view the full press release, visit https://ibn.fm/DQoqH

About Earth Science Tech, Inc. (ETST)

Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness sector. The Company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company’s healthcare operations are supported by investments in real estate and asset management activities and a consumer products business.

The core of the Company’s value proposition is the seamless integration of patient care, from consultation to fulfillment. This is achieved through the synergy of specialized subsidiaries.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN